COVID19: Anti-SARS-CoV-2 Antibodies and Infection Severity
COVID19:抗 SARS-CoV-2 抗体和感染严重程度
基本信息
- 批准号:10152299
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAmino AcidsAntibodiesAntibody ResponseAntibody SpecificityAntigenic SpecificityAntigensAsphyxiaB-Lymphocyte EpitopesBehaviorBiological AssayBreathingCOVID-19COVID-19 mortalityCOVID-19 pandemicCessation of lifeCharacteristicsClinicalContractsCoronavirusDangerousnessDevelopmentDiagnostic testsDiseaseDisease OutcomeDisease modelDonor SelectionEnzyme-Linked Immunosorbent AssayEpidemiologyEpitope spreadingEpitopesFormulationFunctional disorderHealthcare SystemsHumanHuman Herpesvirus 4Immune responseIndividualInfectionInfectious AgentInflammatory ResponseKnowledgeKu70 proteinLearningLibrariesLung diseasesLupusMapsMediatingMiddle East Respiratory SyndromeMinorMorbidity - disease rateOccupationsOutcomePassive ImmunotherapyPathogenicityPatient CarePatientsPeptidesPhage DisplayPhasePlasmaPolyethylenesPopulationPropertyProteinsPublic HealthReagentRecombinant ProteinsResearch PersonnelResolutionRiskSARS coronavirusSARS-CoV-2 antibodySARS-CoV-2 antigenSARS-CoV-2 infectionScourgeSevere Acute Respiratory SyndromeSeveritiesSeverity of illnessSolidSourceSpecificityStructureTechniquesTestingTherapeuticTimeVaccinationVaccine DesignVeteransVirusWestern BlottingWorkbasebiosafety level 3 facilitycomorbidityexperienceexperimental studyglycosylationlung injurymilitary veteranolder menpandemic diseasepreventtheoriestherapy designvaccine response
项目摘要
The new Covid-19 virus is deadly for 0.2% to 4% of people infected, with older men the most severely afflicted
with this scourge, being mortal to ~15% of those infected over 80 years, making the US Veteran population
especially vulnerable. It is critically important to understand the mechanisms of this lethal pathophysiology in
order to design interventions that will save lives. MERS, SARS-CoV, and now the new human Covid-19 mean
that three coronaviruses have threatened to become horrific public health problems for the entire world; this
last and most recent one, Covid-19, has succeeded.
Some of the antibodies formed against this virus appear to accentuate the clinical severity of disease, possibly
making the specific details of the immune response responsible for the demise of many infected patients. We
have had more than two decades of experience as VA Merit supported investigators exploring the antigenic
structure of the lupus autoantigens, leading us to the theory that Epstein-Barr virus causes lupus, which is a
hypothesis now supported by convincing circumstantial evidence. We propose to apply our experience to
exploring the details of the fine antigenic specificity of the anti-Covid-19 antibody response in order to
understand what specific antibodies are dangerous. We propose to explore two hypotheses:
Hypothesis 1. Specific and detailed knowledge of antibody immune responses to Covid-19 will be
useful for elucidating pathogenic mechanisms, predicting disease severity, designing vaccines,
selecting therapeutic plasmas, making patient care decisions, informing population epidemiology,
determining infection dynamics, and choosing individual behaviors in the face of the Covid-19
pandemic.
Hypothesis 2. Anti-Covid-19 antibody fine antigenic specificity will correlate with clinical
manifestations and infection severity.
We propose two aims:
Aim 1. Develop and apply assays to dissect the antigenic fine specificity of antibodies forming against shared
and sub-strain specific Covid-19 antigens in the natural human Covid-19 infection.
Aim 2. Isolate and purify anti-Covid-19 antibodies against the major epitopes and any specific antibodies that
are associated with severe pulmonary disease.
We will use Western blotting, solid phase assays (ELISAs), phage display libraries expressing 30-mer amino
acid peptides, and synthesized overlapping fmoc peptides to fully characterize the fine specificity antibody
response to the Covid-19 virus. We will obtain plasma and serum from Veterans and others which we will
evaluate for correlates with clinical outcome. We will isolate individual specificities and characterize their
properties with respect to type, isotype, glycosylation, and activity. We will perform pseudotype assays on
whole repertoires and individual antibody specificities in BSL2 and test for confirmation with neutralization with
collaborators with BSL3 facilities. From these studies we hope to learn how to identify Veterans who are likely
to have a more severe illness and provide clues for developing approaches that could succeed in ameliorating
infection severity and prevent severe disease.
新型冠状病毒对0.2%至4%的感染者是致命的,老年男性受影响最严重
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH M KAUFMAN其他文献
KENNETH M KAUFMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH M KAUFMAN', 18)}}的其他基金
COVID19: Anti-SARS-CoV-2 Antibodies and Infection Severity
COVID19:抗 SARS-CoV-2 抗体和感染严重程度
- 批准号:
10371080 - 财政年份:2021
- 资助金额:
-- - 项目类别:
DNA Binding of Human and Viral Transcription Factors is Associated with Rheumatoid Arthritis Risk Loci
人类和病毒转录因子的 DNA 结合与类风湿关节炎风险位点相关
- 批准号:
9562248 - 财政年份:2018
- 资助金额:
-- - 项目类别:
DNA Binding of Human and Viral Transcription Factors is Associated with Rheumatoid Arthritis Risk Loci
人类和病毒转录因子的 DNA 结合与类风湿关节炎风险位点相关
- 批准号:
10045951 - 财政年份:2018
- 资助金额:
-- - 项目类别:
DNA Binding of Human and Viral Transcription Factors is Associated with Rheumatoid Arthritis Risk Loci
人类和病毒转录因子的 DNA 结合与类风湿关节炎风险位点相关
- 批准号:
10421240 - 财政年份:2018
- 资助金额:
-- - 项目类别:
SNP Confirmation and High Throughput Genotyping Core
SNP 确认和高通量基因分型核心
- 批准号:
7938655 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Comprehensive Genotyping for Susceptibility to Metabolic Muscle Disease
代谢性肌肉疾病易感性的综合基因分型
- 批准号:
7539777 - 财政年份:2008
- 资助金额:
-- - 项目类别:
相似海外基金
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
- 批准号:
2888395 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
- 批准号:
10728925 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
-- - 项目类别: